

Hypervalent organochalcogenanes as inhibitors of protein tyrosine phosphatases†

Leandro Piovan,^a Li Wu,^b Zhong-Yin Zhang^{*b} and Leandro H. Andrade^{*a}

Received 18th November 2010, Accepted 22nd December 2010

DOI: 10.1039/c0ob01050b

A series of organochalcogenanes was synthesized and evaluated as protein tyrosine phosphatases (PTPs) inhibitors. The results indicate that organochalcogenanes inactivate the PTPs in a time- and concentration-dependent fashion, most likely through covalent modification of the active site sulfur-moiety by the chalcogen atom. Consequently, organochalcogenanes represent a new class of mechanism-based probes to modulate the PTP-mediated cellular processes.

Introduction

The prospection of tellurium and selenium compounds exhibiting biological activity has been increased in the last decades, especially after a series of studies that have demonstrated the biological potential of these exotic compounds.¹ Antioxidant activity,² anti-inflammatory properties,^{3,4} neuroprotective and convulsant effects,⁵ cancer prevention,⁶ apoptotic events,⁷ and immunomodulator activities⁸ are some of the biological properties that have been documented for selenium and tellurium-containing compounds. The development of small selenium- and tellurium-containing molecules as enzymatic inhibitors is based on the reactivity and high affinity of selenium and tellurium atoms towards thiol-dependent enzymes such as caspases,⁹ tyrosine kinase¹⁰ and cysteine (papain, cathepsins) proteases.¹¹ A particular class of selenium and tellurium compounds that has been less explored in enzymatic inhibition is the hypervalent organochalcogenanes. Recent investigations have shown that organoselenanes and organotelluranes are very potent inhibitors of cysteine cathepsins, a thiol-dependent enzyme.¹² The affinity between the sulfur-moiety from the catalytic site of these enzymes and chalcogen atom (especially tellurium) makes favorable the formation of a $\sigma_{Y-S-Enz}$ ($Y = \text{Se and Te}$, $S-Enz = \text{thiol-dependent enzyme}$) bound in the inhibitory process. Due to their distinct molecular arrangement and charge distribution, the chalcogen, present in these hypervalent compounds, accommodates a positive charge and consequently, become more electrophilic than their chalcogenides congeners.

In this way, based on the reactivity of selenium- and tellurium-containing compounds and their molecular interaction with different enzymes, the investigation of hypervalent chalcogenanes as inhibitors of other thiol-dependent enzymes is warranted. Protein tyrosine phosphatases (PTPs) constitute a large family of cysteine-dependent enzymes that catalyze the hydrolysis of phosphotyrosine residues in proteins.¹³ PTPs, together with protein tyrosine kinases, play a central role in cell signalling by regulating the phosphorylation status and, in turn, the functional properties, of target proteins in various signal transduction pathways.¹⁴ Dysfunction in PTP activity has been linked to the etiology of several human diseases, including cancer, diabetes and obesity, and autoimmune disorders.¹⁵ Consequently, there is intense interest in developing small molecule PTP inhibitors that not only serve as powerful tools to delineate the physiological roles of these enzymes *in vivo*, but also as excellent leads for the development of new therapeutic agents.

Herein, we described a study of the potential use of hypervalent selenium(IV) and tellurium(IV) (organoselenanes and organotelluranes, respectively) as inhibitors of the PTPs (Fig. 1). Besides the presence of chalcogen atoms (Se or Te), these compounds were designed to contain halogen (Cl or Br) atoms and a chiral center. The presence of a methyl group at the benzylic carbon generates an asymmetric center, which offers the possibility of differential recognition of the enantiomers by the enzyme (PTP) and also a good comparison with the achiral congener. The halogens bounded to chalcogen were chosen to evaluate the possible influence of the leaving group stability to the activity of these compounds. In this way, with simple structural modifications a SAR could be established.

Results and discussion

Synthesis of organoselenanes and organotelluranes (1–12)

The synthesis of organoselenanes involved a short and versatile synthetic route, which employed classic reactions of selenium chemistry (Scheme 1).^{12a}

Similar synthetic approaches were used to prepare the organotelluranes congeners. The achiral organotelluranes **3** and **4** were synthesized from bromo-benzylic ether **1a**. A bromo-lithium exchange reaction of **1a** followed by capture with an electrophilic tellurium species (BuTeTeBu) led to telluride **1c** in 79% yield. The desired achiral organotelluranes **3** and **4** were obtained

^aInstituto de Química, Universidade de São Paulo, Av. Prof. Lineu Prestes 748, SP 05508-900, São Paulo, Brazil. E-mail: leandroh@iq.usp.br

^bDepartment of Biochemistry and Molecular Biology, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, Indiana, 46202. E-mail: zyzhang@iupui.edu

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c0ob01050b





Fig. 1 Selenanes and telluranes evaluated as inhibitors of Protein Tyrosin Phosphatase.




Scheme 1 Synthesis of organoselenanes 1–2, 5–6 and 9–10.^{12a}

(Scheme 2-A) by a tellurium oxidation reaction with SO_2Cl_2 or Br_2 . In order to acquire the chiral organotelluranes (7–8, 11–12) a chemo-enzymatic methodology was developed. In this way, (*RS*)-1-phenylethanol **1g** was submitted to enzymatic kinetic resolution (EKR) through enantioselective transesterification reaction mediated by *Candida antartica* lipase-B (CAL-B). This reaction led to alcohol (*S*)-**1g** and the ester (*R*)-**1h** in high enantiomeric excess (> 99%) and yield (45%), for each product. After hydrolysis of (*R*)-**1h**, the BuTe- group was introduced to each enantiomer of **1g**. An *ortho*-lithiation reaction of (*S*)- or (*R*)-**1g** followed by its capture with BuTeTeBu led to the telluroalcohols (*S*)- or (*R*)-**1i** in good yields (46%). *O*-Methylation of the (*S*)- and (*R*)-**1i** and, finally, reaction of tellurides (*S*)- and (*R*)-**1j** with SO_2Cl_2 or Br_2 led to organotelluranes 7–8, 11–12 (Scheme 2-B).

Assessment of organoselenanes and organotelluranes as PTP inhibitors

The PTPs share a conserved active site and a common catalytic mechanism that features a highly nucleophilic Cys residue.¹³ This active site Cys displays an unusually low $\text{p}K_{\text{a}}$ of ~5,¹⁶ and is situated at the bottom of the phosphotyrosine-binding pocket (*i.e.* the active site) such that its Sy atom is poised 3 Å from the phosphorus atom of phosphotyrosine.¹⁷ In the catalytic mechanism, the active site Cys initiates a nucleophilic attack on the phosphorus atom, leading to the formation of a thiophosphoryl enzyme intermediate. Hydrolysis of this covalent enzyme intermediate then completes the catalytic cycle.

Given the reactivity of selenium and tellurium atoms towards thiol-dependent enzymes, we reasoned that the organochalcogenanes may also display inhibitory activity against the PTPs.



Scheme 2 Reagents and conditions: (i) a: *t*-BuLi, THF ($-78-0\text{ }^{\circ}\text{C}$, 30 min); b: BuTeTeBu (r.t., 3 h); (ii) SO_2Cl_2 or Br_2 , THF ($0\text{ }^{\circ}\text{C}$, 15 min); (iii) NaBH_4 , MeOH (r.t., 1 h); (iv) vinyl acetate, CAL-B, hexane ($32\text{ }^{\circ}\text{C}$, 7 h); (v) K_2CO_3 , MeOH, H_2O (r.t. overnight); (vi) a: *n*-BuLi, TMEDA, pentane (reflux, 24 h), b: BuTeTeBu ($0\text{ }^{\circ}\text{C}$ - r.t., 2 h); (vii) a: NaH, THF ($0\text{ }^{\circ}\text{C}$, 30 min), b: MeI (r.t., 2 h).

To determine whether organoselenanes and organotelluranes (**1–12**) can function as mechanism-based PTP inhibitors, we first examined for their effect on PTP activity using *para*-nitrophenyl phosphate (*p*NPP) as a substrate (see ESI†). All 12 compounds inactivated PTP1B and the PTP from *Yersinia* YopH in a time-dependent first order process (Table 1).

These assays were very important to identify the relevance of the chalcogen atom for the profile of the organochalcogenanes as inhibitor of PTPs. As we can see in Table 1, the values of k_{obs} showed that organotelluranes are more potent than organoselenanes for inhibition of PTP1B and the YopH. However, the contributions of the halogens and a possible stereochemistry discrimination of

these compounds were not clear from the observed SAR towards the PTPs.

Inactivation of the PTPs by organoselenanes and organotelluranes appeared irreversible as extensive dialysis and/or buffer exchange of the reaction mixture failed to recover enzyme activity.

Since organotelluranes displayed higher inhibitory profile than organoselenanes, **3** was chosen as a model inhibitor, to perform a more detailed kinetic analysis in the PTP1B inactivation. Analysis of the pseudo-first-order rate constant as a function of inhibitor concentration showed that compound **3**-mediated PTP1B inactivation displayed saturation kinetics (Fig. 2), yielding values for the equilibrium binding constant K_i and the inactivation
















Fig. 2 Kinetic analysis of PTP1B inactivation by **3** at $25\text{ }^{\circ}\text{C}$ and pH 7. Panel on the left: time and concentration dependence of inhibitor **3**-mediated PTP1B inactivation. Compound **3** concentrations were as follows: ● 6 μM , □ 10 μM , ▲ 18 μM , ▽ 33 μM , ◆ 59 μM , ○ 106 μM , ● 190 μM , △ 343 μM , ▽ 617 μM , ◇ 1111 μM , and ■ 2000 μM . Panel on the right: Concentration dependence of the pseudo-first-order rate constants k_{obs} for **3**-mediated PTP1B inactivation.

Table 1 Rate constants for onset inactivation of the PTPs by organochalcogenanes 1–12

Structure	Inactivator Code	PTP1B ^a (k_{obs} , min ⁻¹)	YopH ^b (k_{obs} , min ⁻¹)
	1	0.46 ± 0.15	0.25 ± 0.17
	2	0.48 ± 0.12	0.39 ± 0.22
	3	0.53 ± 0.25	0.89 ± 0.21
	4	0.30 ± 0.19	0.92 ± 0.19
	5	0.22 ± 0.25	0.18 ± 0.12
	6	0.21 ± 0.18	0.09 ± 0.14
	7	0.43 ± 0.25	0.74 ± 0.22
	8	0.31 ± 0.15	0.59 ± 0.10
	9	0.20 ± 0.16	0.39 ± 0.20
	10	0.20 ± 0.23	0.30 ± 0.11
	11	0.46 ± 0.19	1.07 ± 0.46
	12	0.60 ± 0.39	0.65 ± 0.46

^a [inactivator] = 0.05 mM; ^b [inactivator] = 0.1 mM

rate constant k_i of 1.9 ± 0.17 mM and 17.2 ± 0.9 min⁻¹, respectively. These results suggest that **3** is an active site-directed affinity agent

whose mode of action likely involves at least two steps: binding to the PTP active site followed by covalent modification of the active site Cys residue. It is worthwhile to point out that the kinetic parameters K_i and k_i for compound **3** compare very favorably to those determined for previously described activity-based probes for the PTPs, including α -bromobenzyl phosphonate¹⁸ and aryl vinyl sulfonates.¹⁹

In summary, the results highlight the potential for developing hypervalent chalcogenated based small molecule probes to modulate PTP activity in signaling and in diseases. Among the organochalcogenanes used as inhibitor of PTPs, organotelluranes showed to be more potent than organoselenanes for inhibition of PTP1B and the YopH. The general reactivity of the organotelluranes toward the PTPs should facilitate the design of novel activity-based PTP probes. Additionally, PTP isozyme-specific organotelluranes based inhibitors could be developed by introducing specificity determinants into the aryl group to increase potency and selectivity.

Acknowledgements

L.W. and Z.-Y.Z. were supported in part by the National Institutes of Health Grants CA126937 and CA152194. L.P. and L.H.A. thank CNPq, CAPES and FAPESP for financial support.

References

- L. A. Ba, M. Döring, V. Jamier and C. Jacob, *Org. Biomol. Chem.*, 2010, **8**, 4203–4216.
- (a) M. McNaughton, L. Engman, A. Birmingham, G. Powis and I. A. Cotgreave, *J. Med. Chem.*, 2004, **47**, 233–239; (b) T. Kanda, L. Engman, I. A. Cotgreave and G. J. Powis, *J. Org. Chem.*, 1999, **64**, 8161–8169; (c) E. Wieslander, L. Engman, E. Svensjo, M. Erlansson, U. Johansson, M. Linden, C.-M. Andersson and R. Brattsand, *Biochem. Pharmacol.*, 1998, **55**, 573–584.
- (a) L. H. Duntas, *Horm. Metab. Res.*, 2009, **41**, 443–447; (b) K. P. Bhabak and G. Mugesh, *Chem.–Asian J.*, 2009, **4**, 974–983.
- M. Brodsky, G. Halpert, M. Albeck and B. Sredni, *J. Inflammation*, 2010, **7**, 3.
- (a) S. Pinton, J. L. da Rocha, G. Zeni and C. W. Nogueira, *Neurosci. Lett.*, 2010, **472**, 56–60; (b) M. Prigol, S. Pinton, R. F. Schumacher, C. W. Nogueira and G. Zeni, *Arch. Toxicol.*, 2010, **84**, 373–378; (c) M. Prigol, R. F. Schumacher, C. W. Nogueira and G. Zeni, *Toxicol. Lett.*, 2009, **189**, 35–39.
- (a) G. N. Schrauzer, *Crit. Rev. Biotechnol.*, 2009, **29**, 10–17; (b) U. Gundimeda, J. E. Schiffman, S. N. Gottlieb, B. I. Roth and R. Gopalakrishna, *Carcinogenesis*, 2009, **30**, 1553–1561; (c) J. Fleming, A. Ghose and P. R. Harrison, *Nutr. Cancer*, 2001, **40**, 42–49; (d) H. E. Ganther, *Carcinogenesis*, 1999, **20**, 1657–1666; (e) G. F. Combs Jr. and W. P. Gray, *Pharmacol. Ther.*, 1998, **79**, 179–192.
- (a) C. Sanmartin, D. Plano and J. A. Palop, *Mini-Rev. Med. Chem.*, 2008, **8**, 1020–1031; (b) R. Sinha and K. El-Bayoumy, *Curr. Cancer Drug Targets*, 2004, **4**, 13–28; (c) N. Zhou, H. Xiao, T.-K. Li, A. Nur-E-Kamal and L. F. Liu, *J. Biol. Chem.*, 2003, **278**, 29532–29537.
- A. Carmely, D. Meirou, A. Peretz, M. Albeck, B. Bartoov and B. Sredni, *Hum. Reprod.*, 2009, **24**, 1322–1329.
- E. Okun, T. V. Arumugam, S. C. Tang, M. Gleichmann, M. Albeck, B. Sredni and M. P. Mattson, *J. Neurochem.*, 2007, **102**, 1232–1241.
- R. Hayun, S. Shpungin, H. Malovani, M. Albeck, E. Okun, U. Nir and B. Sredni, *Ann. N. Y. Acad. Sci.*, 2007, **1095**, 240–250.
- A. Albeck, H. Weitman, B. Sredni and M. Albeck, *Inorg. Chem.*, 1998, **37**, 1701–1712.
- (a) L. Piovani, M. F. M. Alves, L. Juliano, D. Bromme, R. L. O. R. Cunha and L. H. Andrade, *J. Braz. Chem. Soc.*, 2010, **21**, 2108–2118; (b) R. L. O. R. Cunha, I. E. Gouvêa, G. P. V. Feitosa, M. F. M. Alves, D. Bromme, J. V. Comasseto, I. L. S. Tersariol and L. Juliano, *Biol. Chem.*, 2009, **390**, 1205–1212; (c) R. L. O. R. Cunha, M. E. Urano, J. R. Chagas, P. C. Almeida, C. Bincoletto, I. L. S. Tersariol and J. V.

-
- Comasseto, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 755–760; (d) D. S. Persike, R. L. O. R. Cunha, L. Juliano, I. R. Silva, F. E. Rosim, T. Vignoli, F. Dona, E. A. Cavalheiro and M. J. S. Fernandes, *Neurobiol. Dis.*, 2008, **31**, 120–126.
- 13 Z.-Y. Zhang, *Prog. Nucleic Acid Res. Mol. Biol.*, 2003, **73**, 171–220.
14 N. K. Tonks, *Nat. Rev. Mol. Cell Biol.*, 2006, **7**, 833–846.
15 Z.-Y. Zhang, *Curr. Opin. Chem. Biol.*, 2001, **5**, 416–423.
- 16 Z.-Y. Zhang and J. E. Dixon, *Biochemistry*, 1993, **32**, 9340–9345.
17 Z. Jia, D. Barford, A. J. Flint and N. K. Tonks, *Science*, 1995, **268**, 1754–1758.
18 S. Kumar, B. Zhou, F. Liang, W.-Q. Wang, Z. Huang and Z.-Y. Zhang, *Proc. Natl. Acad. Sci. U. S. A.*, 2004, **101**, 7943–7948.
19 S. Liu, B. Zhou, H. Yang, Y. He, Z.-X. Jiang, S. Kumar, L. Wu and Z.-Y. Zhang, *J. Am. Chem. Soc.*, 2008, **130**, 8251–8260.